Angiotensin-receptor blockers in heart failure: evidence from the CHARM trial.

Abstract

The large Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) trial recently found that in patients with heart failure who were similar to those whom clinicians see in everyday practice, the angiotensin-receptor blocker candesartan was not only an acceptable alternative to angiotensin-converting enzyme (ACE) inhibitors, but also was beneficial when added to regimens that already included ACE inhibitors and beta-blockers. Candesartan was beneficial in heart failure patients with or without left ventricular systolic dysfunction.

• Authors: Shyam Bhakta, Mark E Dunlap
• Journal: Cleveland Clinic journal of medicine (Cleve Clin J Med) Vol. 71 Issue 8 Pg. 665-73 (Aug 2004) ISSN: 0891-1150 [Print] United States
• PMID: 15449762 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Angiotensin II Type 1 Receptor Blockers
• Angiotensin-Converting Enzyme Inhibitors
• Antihypertensive Agents
• Benzimidazoles
• Biphenyl Compounds
• Tetrazoles
• candesartan

Topics

• Angiotensin II Type 1 Receptor Blockers
• Angiotensin-Converting Enzyme Inhibitors (adverse effects)
• Antihypertensive Agents (therapeutic use)
• Benzimidazoles (therapeutic use)
• Biphenyl Compounds
• Heart Failure (drug therapy)
• Humans
• Randomized Controlled Trials as Topic
• Tetrazoles (therapeutic use)